
Ranbaxy Laboratories Ltd has received approval from USFDA for manufacturing and marketing Doxycycline Tablets in the US market.
The company informed the Bombay Stock Exchange that it got the approval for marketing the antibiotic in strengths of 50mg, 75mg and 100mg.
Doxycycline is indicated for a variety of infections caused by susceptible strains or micro-organisms including respiratory tract and urinary tract infections, skin and skin structure infections, it added.
Source:PTI News